• Can-Fite BioPharma scheduled annual general meeting in Ramat Gan, Israel on May 28, 2026.
• Shareholders to vote on re-election of Abraham Sartani as Class I director for a new three-year term.
• Meeting to consider increasing authorized share capital to 30,000,000 ordinary shares from 14,000,000.
• Investors to vote on option grants of 24,000 options each to Chairman Pnina Fishman and CEO/CFO Motti Farbstein.
• Agenda includes reappointment of Kost Forer Gabbay & Kasierer (Ernst & Young Global member firm) as independent auditor for year ending Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-047088), on April 23, 2026, and is solely responsible for the information contained therein.